Inventor · disambiguated record
Esther Breij
Also filed as: BREIJ ESTHER · BREIJ ESTHER C W · BREIJ ESTHER CORNELIA WILHELMINA
15 granted patents·20 pending applications·47 citations·filing 2008–2025
91Inventor score
Top patents by PatentIndex Score
35 records- 0193US10544220B2Bispecific antibodies against CD3 and CD20GENMAB AS·Filed 2016·Granted Jan 28, 2020·18 cites·12 claims
- 0291US11008399B2AntibodiesGENMAB AS·Filed 2020·Granted May 18, 2021·2 cites·22 claims
- 0390US10201607B2Antibodies binding AXLGENMAB AS·Filed 2018·Granted Feb 12, 2019·7 cites·28 claims
- 0489US10765743B2Antibodies binding AXLGENMAB AS·Filed 2019·Granted Sep 8, 2020·3 cites·46 claims
- 0588US11130819B2AntibodiesGENMAB AS·Filed 2021·Granted Sep 28, 2021·1 cites·30 claims
- 0687US10500276B2Antibodies binding AXLGENMAB AS·Filed 2019·Granted Dec 10, 2019·4 cites·35 claims
- 0786US10512688B2Antibodies binding AXLGENMAB AS·Filed 2015·Granted Dec 24, 2019·4 cites·8 claims
- 0885US8802089B2Monoclonal antibodies against CD32BVAN DEN BRINK EDWARD NORBERT·Filed 2008·Granted Aug 12, 2014·7 cites·36 claims
- 0979US12410258B2Antibodies capable of binding to OX40, variants thereof and uses thereofGENMAB AS·Filed 2024·Granted Sep 9, 2025·0 cites·23 claims
- 1076US11970544B2AntibodiesGENMAB AS·Filed 2021·Granted Apr 30, 2024·0 cites·31 claims
- 1176US2020171152A1Antibodies binding axlGENMAB AS·Filed 2019·Application pending·0 cites
- 1275US2023321261A1Axl-specific antibody-drug conjugates for cancer treatmentGENMAB AS·Filed 2022·Application pending·0 cites
- 1373US11261254B1AntibodiesGENMAB AS·Filed 2021·Granted Mar 1, 2022·0 cites·30 claims
- 1473US2023212301A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 1572US2023109496A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 1671US11814437B2Antibodies binding to CD30 and CD3GENMAB AS·Filed 2022·Granted Nov 14, 2023·0 cites·16 claims
- 1771US9663578B2Monoclonal antibodies against CD32bGENMAB AS·Filed 2014·Granted May 30, 2017·1 cites·16 claims
- 1871US2025289900A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB AS·Filed 2025·Application pending·0 cites
- 1971US2025289899A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB AS·Filed 2025·Application pending·0 cites
- 2066US2023076417A1Multispecific antigen-binding molecule with improved internalization characteristicsGENMAB AS·Filed 2022·Application pending·0 cites
- 2165US2020397913A1Axl-specific antibody-drug conjugates for cancer treatmentGENMAB AS·Filed 2020·Application pending·0 cites
- 2263US2025333526A1Antibodies capable of binding to ox40, variants thereof and uses thereofGENMAB AS·Filed 2025·Application pending·0 cites
- 2363US2025333527A1Antibodies capable of binding to ox40, variants thereof and uses thereofGENMAB AS·Filed 2025·Application pending·0 cites
- 2462US2019022243A1Axl-specific antibody-drug conjugates for cancer treatmentGENMAB AS·Filed 2017·Application pending·0 cites
- 2560US2018326084A1Axl-specific antibody-drug conjugates for cancer treatmentGENMAB AS·Filed 2016·Application pending·0 cites
- 2659US2025325643A1Binding agents capable of binding to cd27 in combination therapyGENMAB AS·Filed 2023·Application pending·0 cites
- 2758US12398214B2Binding agents binding to EpCAM and CD137GENMAB AS·Filed 2023·Granted Aug 26, 2025·0 cites·24 claims
- 2857US11932693B2Monoclonal antibodies directed against programmed death-1 protein and their use in medicineBioNTech SE·Filed 2023·Granted Mar 19, 2024·0 cites·30 claims
- 2955US2025002600A1Multispecific binding agents against pd-l1 and cd137 in combination therapyGENMAB AS·Filed 2022·Application pending·0 cites
- 3052US2024327544A1Multispecific binding agents against cd40 and cd137 in combination therapy for cancerBioNTech SE·Filed 2022·Application pending·0 cites
- 3150US2021393793A1Axl-specific antibodies for treatment of non-small cell lung cancerGENMAB AS·Filed 2019·Application pending·0 cites
- 3247US2021070869A1Axl-specific antibodies for cancer treatmentGENMAB AS·Filed 2019·Application pending·0 cites
- 3347US2022273809A1Axl antibody-drug conjugates for use in treating cancerGENMAB AS·Filed 2020·Application pending·0 cites
- 3447US2019352423A1Multispecific antigen-binding molecule with improved internalization characteristicsGENMAB AS·Filed 2017·Application pending·0 cites
- 3545US2021030888A1Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancerGENMAB AS·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Esther Breij files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →